WALTHAM, Mass., May 3, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that members of the company’s leadership team will be featured speakers on advances in the protein degradation field at two upcoming drug discovery conferences.
Effie Tozzo, PhD, Chief Scientific Officer of Avilar, will deliver a keynote address on the topic of extracellular protein degradation at the 9th annual Drug Discovery Strategic Summit being held May 9-10, 2022, in Boston. Dr. Tozzo’s presentation will describe how the company has developed and integrated a suite of technologies tailored for the design and optimization of ATACs (ASGPR Targeting Chimeras), novel protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. She will also highlight initial proof-of-concept studies and in vitro characterization of ATAC interactions with ASGPR and target protein, including binding, cellular uptake, and degradation via the endolysosomal pathway.
Daniel Grau, Chief Executive Officer and President of Avilar, will participate in a panel session on novel protein degraders at the 33rd annual Cancer Progress Conference being held virtually on May 10-12, 2022.
Details of the keynote address and panel session are as follows:
——————————————————
Keynote Address: Extracellular Protein Targeted Degradation with Novel ATACs (ASGPR Targeting Chimeras
Event: 9th annual Drug Discovery Strategic Summit being held May 9-10, 2022, Boston
Date: Monday, May 9, 2022, 1:20 p.m. ET
——————————————————
Panel Session: Degraders and Beyond: The Rise of Diverse Heterobifunctional Molecules
Event: 33rd Annual Cancer Progress Conference (virtual)
Date: Wednesday, May 11, 2022, 3:30 p.m. ET
About Avilar Therapeutics
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA. For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.
Media Contact:
Kathryn Morris
The Yates Network
914-204-6412